Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California. more
Time Frame | CORT | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.39% | -0.33% | -1.49% |
1-Month Return | -11.62% | -4.57% | -0.37% |
3-Month Return | 18.57% | -9.96% | 3.89% |
6-Month Return | 70.55% | -5.67% | 9.34% |
1-Year Return | 60.92% | 2.53% | 25.19% |
3-Year Return | 165.9% | -1.43% | 24.7% |
5-Year Return | 313.06% | 34.73% | 85.39% |
10-Year Return | 1674.49% | 102.14% | 187.19% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 306.49M | 353.87M | 365.98M | 401.86M | 482.38M | [{"date":"2019-12-31","value":63.54,"profit":true},{"date":"2020-12-31","value":73.36,"profit":true},{"date":"2021-12-31","value":75.87,"profit":true},{"date":"2022-12-31","value":83.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 5.50M | 5.58M | 5.28M | 5.38M | 6.48M | [{"date":"2019-12-31","value":84.93,"profit":true},{"date":"2020-12-31","value":86.13,"profit":true},{"date":"2021-12-31","value":81.48,"profit":true},{"date":"2022-12-31","value":83.09,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 300.98M | 348.29M | 360.70M | 396.47M | 475.89M | [{"date":"2019-12-31","value":63.25,"profit":true},{"date":"2020-12-31","value":73.19,"profit":true},{"date":"2021-12-31","value":75.79,"profit":true},{"date":"2022-12-31","value":83.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 98.20% | 98.42% | 98.56% | 98.66% | 98.66% | [{"date":"2019-12-31","value":99.54,"profit":true},{"date":"2020-12-31","value":99.76,"profit":true},{"date":"2021-12-31","value":99.9,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 189.38M | 220.09M | 236.22M | 283.84M | 368.61M | [{"date":"2019-12-31","value":51.38,"profit":true},{"date":"2020-12-31","value":59.71,"profit":true},{"date":"2021-12-31","value":64.08,"profit":true},{"date":"2022-12-31","value":77,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 111.61M | 128.20M | 124.48M | 112.63M | 107.28M | [{"date":"2019-12-31","value":87.05,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.09,"profit":true},{"date":"2022-12-31","value":87.86,"profit":true},{"date":"2023-12-31","value":83.68,"profit":true}] |
Total Non-Operating Income/Expense | 10.14M | 6.80M | 1.06M | 7.11M | 34.55M | [{"date":"2019-12-31","value":29.35,"profit":true},{"date":"2020-12-31","value":19.68,"profit":true},{"date":"2021-12-31","value":3.06,"profit":true},{"date":"2022-12-31","value":20.59,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | 116.68M | 131.60M | 125.01M | 116.19M | 124.56M | [{"date":"2019-12-31","value":88.66,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":94.99,"profit":true},{"date":"2022-12-31","value":88.29,"profit":true},{"date":"2023-12-31","value":94.65,"profit":true}] |
Income Taxes | 22.50M | 25.59M | 12.49M | 14.77M | 18.42M | [{"date":"2019-12-31","value":87.9,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":48.82,"profit":true},{"date":"2022-12-31","value":57.73,"profit":true},{"date":"2023-12-31","value":71.97,"profit":true}] |
Income After Taxes | 94.18M | 106.01M | 112.51M | 101.42M | 106.14M | [{"date":"2019-12-31","value":83.71,"profit":true},{"date":"2020-12-31","value":94.22,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.14,"profit":true},{"date":"2023-12-31","value":94.34,"profit":true}] |
Income From Continuous Operations | 94.18M | 106.01M | 112.51M | 101.42M | 106.14M | [{"date":"2019-12-31","value":83.71,"profit":true},{"date":"2020-12-31","value":94.22,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.14,"profit":true},{"date":"2023-12-31","value":94.34,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 94.18M | 106.01M | 112.51M | 101.42M | 106.14M | [{"date":"2019-12-31","value":83.71,"profit":true},{"date":"2020-12-31","value":94.22,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.14,"profit":true},{"date":"2023-12-31","value":94.34,"profit":true}] |
EPS (Diluted) | 0.78 | 0.85 | 0.89 | 0.88 | 0.95 | [{"date":"2019-12-31","value":82.11,"profit":true},{"date":"2020-12-31","value":89.47,"profit":true},{"date":"2021-12-31","value":93.68,"profit":true},{"date":"2022-12-31","value":92.63,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
CORT | |
---|---|
Cash Ratio | 3.01 |
Current Ratio | 3.70 |
Quick Ratio | 3.64 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CORT | |
---|---|
ROA (LTM) | 13.00% |
ROE (LTM) | 25.77% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CORT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.19 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.81 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CORT | |
---|---|
Trailing PE | 40.40 |
Forward PE | 28.25 |
P/S (TTM) | 8.48 |
P/B | 8.44 |
Price/FCF | 74 |
EV/R | 7.98 |
EV/Ebitda | 34.70 |
PEG | 0.61 |
Corcept Therapeutics Incorporated (CORT) share price today is $52.17
Yes, Indians can buy shares of Corcept Therapeutics Incorporated (CORT) on Vested. To buy Corcept Therapeutics Incorporated from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CORT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Corcept Therapeutics Incorporated (CORT) via the Vested app. You can start investing in Corcept Therapeutics Incorporated (CORT) with a minimum investment of $1.
You can invest in shares of Corcept Therapeutics Incorporated (CORT) via Vested in three simple steps:
The 52-week high price of Corcept Therapeutics Incorporated (CORT) is $62.22. The 52-week low price of Corcept Therapeutics Incorporated (CORT) is $20.84.
The price-to-earnings (P/E) ratio of Corcept Therapeutics Incorporated (CORT) is 40.3968
The price-to-book (P/B) ratio of Corcept Therapeutics Incorporated (CORT) is 8.44
The dividend yield of Corcept Therapeutics Incorporated (CORT) is 0.00%
The market capitalization of Corcept Therapeutics Incorporated (CORT) is $5.33B
The stock symbol (or ticker) of Corcept Therapeutics Incorporated is CORT